Loading...
•
Jun 30, 2022
Blueprint Medicines Q2 2022 Earnings Report
Blueprint Medicines reported second quarter 2022 results, achieving $36.5 million in total revenues, including $28.5 million in AYVAKIT net product revenues.
Key Takeaways
Blueprint Medicines reported $36.5 million in total revenues for Q2 2022, including $28.5 million from AYVAKIT. The company is on track to announce topline data from the PIONEER trial in August and has over $1 billion in cash on its balance sheet.
Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT net product revenues.
AYVAKIT revenue grew 20% from Q1 2022.
Plan to report topline data for registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in August 2022.
Licensed KIT exon 13 inhibitor to IDRx in exchange for a 15 percent Series A preferred equity investment, and the potential to receive up to $217.5 million in development, regulatory, and sales-based milestones and tiered percentage royalties.
Forward Guidance
Blueprint Medicines anticipates approximately $180M to $200M in total revenues in 2022, including approximately $115M to $130M in AYVAKIT net product revenues. The company continues to expect that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...